RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect

RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect

Non-coding uridine-rich small nuclear RNAs (UsnRNAs) have emerged in recent years as effective tools for exon skipping for the treatment of Duchenne muscular dystrophy (DMD), a degenerative muscular genetic disorder. We recently showed the high capacity of a recombinant adeno-associated virus (rAAV)...

Full description

Bibliographic Details
Main Authors:	Claire Domenger, Marine Allais, Virginie François, Adrien Léger, Emilie Lecomte, Marie Montus, Laurent Servais, Thomas Voit, Philippe Moullier, Yann Audic, Caroline Le Guiner
Format:	Article
Language:	English
Published:	Elsevier 2018-03-01
Series:	Molecular Therapy: Nucleic Acids
Subjects:	exon skipping off-target RNA sequencing Duchenne U7snRNA
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253117303074

Similar Items

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
by: Nicolas Wein, et al.
Published: (2022-09-01)

RNA-seq analysis of an antisense sequence optimized for exon skipping in Duchenne patients reveals no off-target effect
by: Domenger, C, et al.
Published: (2017)

Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Vassilia Partali, et al.
Published: (2012-01-01)

Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping
by: Tabatha R. Simmons, et al.
Published: (2021-06-01)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
by: Agathe Eckenfelder, et al.
Published: (2012-01-01)

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
by: Philippine Aupy, et al.
Published: (2020-06-01)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
by: Flavien Bizot, et al.
Published: (2022-12-01)

Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
by: Derek W. Wang, et al.
Published: (2018-06-01)

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial
by: Takami Ishizuka, et al.
Published: (2023-06-01)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
by: Michael Gapinske, et al.
Published: (2023-09-01)

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
by: Yusuke Echigoya, et al.
Published: (2018-12-01)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
by: Remko Goossens, et al.
Published: (2023-12-01)

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
by: Liubov V. Gushchina, et al.
Published: (2023-12-01)

Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
by: Kane L Greer, et al.
Published: (2014-01-01)

Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy
by: Francesco Galli, et al.
Published: (2024-03-01)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
by: Alberto Malerba, et al.
Published: (2012-01-01)

Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene
by: Kane Greer, et al.
Published: (2020-06-01)

Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
by: Gökçe Eser, et al.
Published: (2022-07-01)

Prevention of early-onset cardiomyopathy in Dmd exon 52–54 deletion mice by CRISPR-Cas9-mediated exon skipping
by: Matthew Rok, et al.
Published: (2023-09-01)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
by: HaiFang Yin, et al.
Published: (2013-01-01)

Targeted Exon Skipping to Address “Leaky” Mutations in the Dystrophin Gene
by: Sue Fletcher, et al.
Published: (2012-01-01)

Networking to Optimize <i>Dmd</i> exon 53 Skipping in the Brain of <i>mdx52</i> Mouse Model
by: Mathilde Doisy, et al.
Published: (2023-12-01)

Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
by: Michael Gramlich, et al.
Published: (2015-05-01)

Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa
by: Franciscus C. Vermeer, et al.
Published: (2021-11-01)

Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52
by: Jessica M. Cale, et al.
Published: (2021-03-01)

Reverse complementary matches simultaneously promote both back-splicing and exon-skipping
by: Dong Cao
Published: (2021-08-01)

Polypurine Reverse-Hoogsteen Hairpins as a Tool for Exon Skipping at the Genomic Level in Mammalian Cells
by: Véronique Noé, et al.
Published: (2021-04-01)

Prime editing strategies to mediate exon skipping in DMD gene
by: Cedric Happi Mbakam, et al.
Published: (2023-05-01)

Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot
by: Harry Wilton-Clark, et al.
Published: (2022-01-01)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the <i>DMD</i> Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
by: Saeed Anwar, et al.
Published: (2021-01-01)

A <i>Dystrophin</i> Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping
by: Yusuke Echigoya, et al.
Published: (2021-12-01)

RNA-Based Strategies for Cancer Therapy: In Silico Design and Evaluation of ASOs for Targeted Exon Skipping
by: Chiara Pacelli, et al.
Published: (2023-10-01)

Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2′-O-Methyl Mixmer Antisense Oligonucleotide
by: Suxiang Chen, et al.
Published: (2016-11-01)

Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model
by: Flavien Bizot, et al.
Published: (2023-02-01)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
by: Elena Marchesi, et al.
Published: (2022-04-01)

Six Exonic Variants in the SLC5A2 Gene Cause Exon Skipping in a Minigene Assay
by: Sai Wang, et al.
Published: (2020-11-01)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
by: Esra Erkut, et al.
Published: (2022-02-01)

CRISPR-induced exon skipping is dependent on premature termination codon mutations
by: Tingting Sui, et al.
Published: (2018-10-01)

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
by: Theodora Markati, et al.
Published: (2021-11-01)

Exon skipping-rich transcriptomes of animals reflect the significance of exon-shuffling in metazoan proteome evolution
by: Laszlo Patthy
Published: (2019-01-01)